Role and regulation of the thrombin receptor (PAR-1) in human melanoma
暂无分享,去创建一个
[1] L. Zacharski,et al. Treatment of Cancer with Anticoagulants: Rationale in the Treatment of Melanoma , 2001, International journal of hematology.
[2] A. Lombardi,et al. From natural to synthetic multisite thrombin inhibitors. , 1999, Biopolymers.
[3] I. Ellis,et al. Immunohistochemical analysis reveals a tumour suppressor‐like role for the transcription factor AP‐2 in invasive breast cancer , 1999, The Journal of pathology.
[4] P. Grabham,et al. Cellular consequences of thrombin-receptor activation. , 1996, The Biochemical journal.
[5] L. Oberley,et al. A Family of AP-2 Proteins Down-regulate Manganese Superoxide Dismutase Expression* , 2001, The Journal of Biological Chemistry.
[6] R. Tjian,et al. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. , 1991, Science.
[7] M. Tainsky,et al. Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.
[8] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[9] T S Edgington,et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[11] C. Muchardt,et al. RB and c-Myc Activate Expression of the E-Cadherin Gene in Epithelial Cells through Interaction with Transcription Factor AP-2 , 1998, Molecular and Cellular Biology.
[12] J. Henley,et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma , 2005, Journal of Cancer Research and Clinical Oncology.
[13] M. Karin,et al. Upstream promoter element of the human metallothionein-IIA gene can act like an enhancer element. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[14] J W Fenton,et al. Regulation of Thrombin Generation and Functions , 1988, Seminars in thrombosis and hemostasis.
[15] F. Domann,et al. Redox modulation of AP-2 DNA binding activity in vitro. , 1998, Biochemical and biophysical research communications.
[16] R. Weinel,et al. Characterization of Functional Thrombin Receptors in Human Pancreatic Tumor Cells (MIA PACA‐2) , 1998, Pancreas.
[17] H. Hurst,et al. A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines. , 1993, The EMBO journal.
[18] R. Zarnegar,et al. The repressive function of AP2 transcription factor on the hepatocyte growth factor gene promoter. , 2000, Biochemical and biophysical research communications.
[19] A. McMahon,et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2 , 1996, Nature.
[20] R. Tjian,et al. Positive and negative regulation of transcription in vitro: Enhancer-binding protein AP-2 is inhibited by SV40 T antigen , 1987, Cell.
[21] R. Tjian,et al. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. , 1988, Genes & development.
[22] S. Hinrichs,et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment , 2000, Oncogene.
[23] A. Cucina,et al. Thrombin induces production of growth factors from aortic smooth muscle cells. , 1999, The Journal of surgical research.
[24] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[25] E. Lemarié,et al. Subcutaneous heparin treatment increases survival in small cell lung cancer , 1994, Cancer.
[26] P. Altevogt,et al. Tumor Cell Invasion Is Promoted by Activation of Protease Activated Receptor-1 in Cooperation with the αvβ5 Integrin* , 2001, The Journal of Biological Chemistry.
[27] A. Baldi,et al. Expression of AP‐2 transcription factor and of its downstream target genes c‐kit, E‐cadherin and p21 in human cutaneous melanoma , 2001, Journal of cellular biochemistry.
[28] C. Ehrhardt,et al. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. , 1993, Trends in pharmacological sciences.
[29] T. Mohandas,et al. Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter. , 1991, Genomics.
[30] J. Pouysségur,et al. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap , 2001, Oncogene.
[31] M. Runge,et al. Cloning and Identification of Regulatory Sequences of the Human Thrombin Receptor Gene* , 1996, The Journal of Biological Chemistry.
[32] W. Morain,et al. Cellular Localization of Enzymatically Active Thrombin in Intact Human Tissues by Hirudin Binding , 1995, Thrombosis and Haemostasis.
[33] M. Bar‐eli,et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells , 1997, Oncogene.
[34] M. Lane,et al. Sequential repression and activation of the CCAAT enhancer-binding protein-alpha (C/EBPalpha ) gene during adipogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[35] Z. Ronai,et al. Expression and transcriptional activity of Ap‐1, CRE, and URE binding proteins in B16 mouse melanoma subclones , 1994, Molecular carcinogenesis.
[36] S Gaubatz,et al. Transcriptional activation by Myc is under negative control by the transcription factor AP‐2. , 1995, The EMBO journal.
[37] G. Clayman,et al. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. , 2001, Cancer letters.
[38] A. Mutero,et al. Transcription Factor Repression and Activation of the Human Acetylcholinesterase Gene (*) , 1995, The Journal of Biological Chemistry.
[39] S. Karpatkin,et al. Thrombin Induces Increased Expression and Secretion of VEGF from Human FS4 Fibroblasts, DU145 Prostate Cells and CHRF Megakaryocytes , 2001, Thrombosis and Haemostasis.
[40] D. S. St. Clair,et al. Transcriptional regulation of the 5' proximal promoter of the human manganese superoxide dismutase gene. , 1998, DNA and cell biology.
[41] J. Gershenwald,et al. Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.
[42] E. Vitale,et al. Genomic Cloning and Characterization of the Human Thrombin Receptor Gene , 1996, The Journal of Biological Chemistry.
[43] V. Kosma,et al. p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis , 1999, British Journal of Cancer.
[44] A. Bosserhoff,et al. Loss of E-cadherin Expression in Melanoma Cells Involves Up-regulation of the Transcriptional Repressor Snail* , 2001, The Journal of Biological Chemistry.
[45] E. Fuchs,et al. Transcription factor AP2 and its role in epidermal-specific gene expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[46] Jeffrey E Gershenwald,et al. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo , 2001, Oncogene.
[47] W. El-Deiry,et al. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.
[48] K. Honn,et al. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbβ3 expression on the cell surface , 1992 .
[49] D. Massel,et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.
[50] M. Karin,et al. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP , 1987, Cell.
[51] R. Jaenisch,et al. Transcription factor AP-2 essential for cranial closure and craniofacial development , 1996, Nature.
[52] S. Zucker,et al. Thrombin Induces the Activation of Progelatinase A in Vascular Endothelial Cells , 1995, The Journal of Biological Chemistry.
[53] W. Kisiel,et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. , 1990, American journal of clinical pathology.
[54] P. Chambon,et al. The SV40 TC‐II(kappa B) and the related H‐2Kb enhansons exhibit different cell type specific and inducible proto‐enhancer activities, but the SV40 core sequence and the AP‐2 binding site have no enhanson properties. , 1989, The EMBO journal.
[55] S. Hyman,et al. An AP-2 element acts synergistically with the cyclic AMP- and phorbol ester-inducible enhancer of the human proenkephalin gene. , 1989, Molecular and cellular biology.
[56] Regulation of K3 keratin gene transcription by Sp1 and AP-2 in differentiating rabbit corneal epithelial cells. , 1997, Molecular and cellular biology.
[57] D. Clemmons,et al. Transcription Factor AP-2 Regulates Human Insulin-like Growth Factor Binding Protein-5 Gene Expression (*) , 1995, The Journal of Biological Chemistry.
[58] A. Perkins,et al. AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Herlyn,et al. Molecular events in melanoma development and progression. , 1998, Frontiers in bioscience : a journal and virtual library.
[60] R. Tjian,et al. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. , 1989, Genes & development.
[61] R. Kaufmann,et al. Thrombin receptor activation results in calcium signaling and protein kinase C‐dependent stimulation of DNA synthesis in HEp‐2g laryngeal carcinoma cells , 1997, Cancer.
[62] J P Lecocq,et al. Synthetic alpha-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. , 1992, Molecular biology of the cell.
[63] Tatsuya Hayashi,et al. Thrombin stimulates the expression of PDGF in lung epithelial cells. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[64] K. Honn,et al. Thrombin increases the metastatic potential of tumor cells , 1993, International journal of cancer.
[65] V. Kosma,et al. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Swerlick,et al. Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation , 1997, The EMBO journal.
[67] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[68] W. Konigsberg,et al. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[69] R. Tjian,et al. Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40 , 1987, Nature.
[70] R. Tjian,et al. Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. , 1991, Genes & development.
[71] Reuven Reich,et al. Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.
[72] M. Bar‐eli. Gene regulation in melanoma progression by the AP-2 transcription factor. , 2001, Pigment cell research.
[73] B. Pentecost,et al. Role of thrombin receptor in breast cancer invasiveness , 1999, British Journal of Cancer.
[74] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[75] M. Mihm,et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. , 1999, The American journal of pathology.
[76] K. Murakami,et al. Thrombin stimulates production of interleukin‐8 in human umbilical vein endothelial cells , 1996, Immunology.
[77] M. Tainsky,et al. The genomic structure of the human AP-2 transcription factor. , 1994, Nucleic acids research.
[78] R. Kaufmann,et al. Ultraviolet-A-induced transactivation of the vascular endothelial growth factor gene in HaCaT keratinocytes is conveyed by activator protein-2 transcription factor. , 2000, The Journal of investigative dermatology.
[79] L. Zacharski,et al. The Use of Heparin for Treating Human Malignancies , 1999, Pathophysiology of Haemostasis and Thrombosis.
[80] T. Williams,et al. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[81] J. Johnson,et al. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[82] R. Glockshuber,et al. An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2 , 1993, Molecular and cellular biology.
[83] T. Shin,et al. Transcription Factor AP-2 Controls Transcription of the Human Transforming Growth Factor-α Gene* , 1997, The Journal of Biological Chemistry.
[84] D. McConkey,et al. CREB and Its Associated Proteins Act as Survival Factors for Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.